TY - JOUR
T1 - Molecular approach to diagnosis of cardiovascular implantable electronic device infection
AU - Garrigos, Zerelda Esquer
AU - Rizwan Sohail, M.
AU - Greenwood-Quaintance, Kerryl E.
AU - Cunningham, Scott A.
AU - Vijayvargiya, Prakhar
AU - Fida, Madiha
AU - Friedman, Paul A.
AU - Mandrekar, Jayawant
AU - DeSimone, Daniel C.
AU - Baddour, Larry M.
AU - Patel, Robin
N1 - Funding Information:
Financial support. This work was supported by the Mayo Clinic Center for Translational Science Activities grant number UL1TR002377 from the National Center for Advancing Translational Science, a component of the National Institutes of Health (NIH), and NIH grant number R01 AR056647 to R. P.
Funding Information:
Potential conflicts of interest. P. A. F. reports honoraria/consultant fees from Medtronic, Guidant, and Astra Zeneca; a research grant from Medtronic, Astra Zeneca via Beth Israel, Guidant, St. Jude, and Bard; and intellectual property rights with Bard EP, Hewlett Packard, and Medical Positioning, Inc. L. M. B. reports royalty payments (authorship) from UpToDate, Inc, and consultant payments from the American Dental Association and Boston Scientific (all <$20 000). M. R. S. reports receiving funds from Medtronic, Inc, and TRYX, Inc, for prior research unrelated to this study; honoraria/consulting fees from Medtronic, Inc, Spectranetics, Aziyo Biologics, Inc, and Boston Scientific Corporation (all <$20 000). R. P. reports grants from CD Diagnostics, BioFire, Curetis, Merck, Contrafect, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, EnBiotix, Contrafect, and The Medicines Company. R. P. is or has been a consultant to Curetis, Specific Technologies, Selux Dx, GenMark Diagnostics, PathoQuest, Heraeus Medical, and Qvella; monies are paid to Mayo Clinic. In addition, R. P. has a patent on Bordetella pertussis/ parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an antibiofilm substance issued. R. P. receives travel reimbursement from the American Society of Microbiology (ASM) and the Infectious Disease Society of America (IDSA), an editor’s stipend from ASM and IDSA, and honoraria
Publisher Copyright:
© The Author(s) 2019.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Background. Sonicate fluid (SF), a solution derived from vortexing and sonication of explanted cardiovascular implantable electronic devices (CIEDs), is a higher-yield specimen compared with swabs or tissues for culture-based detection of microorganisms associated with CIED infection. Despite this, SF culture fails to identify a causative organism in ~50% of cases. We aimed to evaluate the diagnostic performance of 16S ribosomal RNA gene (rRNA) polymerase chain reaction (PCR)/sequencing of SF and compare it with that of SF culture. Methods. We identified 322 SF specimens from extracted CIEDs and reviewed clinical data for each patient. Subjects were classified as having or not having CIED infection. Cases were subcategorized as culture negative if no significant growth was reported from SF cultures and as culture positive if an organism was detected above predefined thresholds. 16S rRNA PCR/sequencing was performed, with the organisms identified reported according to Clinical and Laboratory Standards Institute guidelines for sequence data interpretation. Results. A total of 278 SF samples corresponded to infected cases, of which 160 were culture positive and 118 culture negative. The remaining 44 were from noninfected cases, of which 2 were culture positive. Compared with SF culture, the sensitivity of 16S rRNA PCR/sequencing was higher (64% vs 57.5%, P = .003). 16S rRNA PCR/sequencing detected a potential pathogen in 28 of 118 culture-negative cases, identifying staphylococci in the majority (18/28). Conclusions. 16S rRNA PCR/sequencing has higher sensitivity to detect bacteria in SF from extracted CIEDs than does SF culture.
AB - Background. Sonicate fluid (SF), a solution derived from vortexing and sonication of explanted cardiovascular implantable electronic devices (CIEDs), is a higher-yield specimen compared with swabs or tissues for culture-based detection of microorganisms associated with CIED infection. Despite this, SF culture fails to identify a causative organism in ~50% of cases. We aimed to evaluate the diagnostic performance of 16S ribosomal RNA gene (rRNA) polymerase chain reaction (PCR)/sequencing of SF and compare it with that of SF culture. Methods. We identified 322 SF specimens from extracted CIEDs and reviewed clinical data for each patient. Subjects were classified as having or not having CIED infection. Cases were subcategorized as culture negative if no significant growth was reported from SF cultures and as culture positive if an organism was detected above predefined thresholds. 16S rRNA PCR/sequencing was performed, with the organisms identified reported according to Clinical and Laboratory Standards Institute guidelines for sequence data interpretation. Results. A total of 278 SF samples corresponded to infected cases, of which 160 were culture positive and 118 culture negative. The remaining 44 were from noninfected cases, of which 2 were culture positive. Compared with SF culture, the sensitivity of 16S rRNA PCR/sequencing was higher (64% vs 57.5%, P = .003). 16S rRNA PCR/sequencing detected a potential pathogen in 28 of 118 culture-negative cases, identifying staphylococci in the majority (18/28). Conclusions. 16S rRNA PCR/sequencing has higher sensitivity to detect bacteria in SF from extracted CIEDs than does SF culture.
KW - 16S rRNA PCR/sequencing
KW - Cardiovascular implantable electronic device infection
KW - Laboratory diagnosis
UR - http://www.scopus.com/inward/record.url?scp=85079355586&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079355586&partnerID=8YFLogxK
U2 - 10.1093/cid/ciz266
DO - 10.1093/cid/ciz266
M3 - Article
C2 - 30944928
AN - SCOPUS:85079355586
SN - 1058-4838
VL - 70
SP - 898
EP - 906
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 5
ER -